NYSE · Health Care

PENUMBRA INC PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Medical/Dental Instruments

Company profile

Business mix

  • It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system.
  • It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25.
  • In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications.
  • Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within medical devices?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 73.89 FCF 1.69% Buyback -0.45%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.3% $276.0M 2026-03-31
Soros Fund Management George Soros 0.7% $66.8M 2026-03-31

Recent trading changes over the last 4 quarters

Net buyers 2 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $116.5M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +51.5% +354,866 / 688,995
Soros Fund Management George Soros 1 filing periods
13F 2026-03-31 Filed 2026-05-15
New Shares - 13F value change +$66.8M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +203,434 (New) Total shares 203,434 Value $66.8M
Baillie Gifford legacy James Anderson 4 filing periods
13F 2025-06-30 Filed 2025-08-06
Major increase Shares 33.8% 13F value change +$52.4M
13F 2025-09-30 Filed 2025-10-31
Minor reduction Shares -1.5% 13F value change -$6.5M
13F 2025-12-31 Filed 2026-01-23
Minor reduction Shares -3.5% 13F value change +$42.3M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -4.1% 13F value change +$3.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 688,995 Last 4 periods +151,432 (+22.0%) Total shares 840,427 Value $276.0M

Recent mentions

No public mentions.